

Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030

<https://marketpublishers.com/r/GB19FFD0ED38EN.html>

Date: June 2024

Pages: 240

Price: US\$ 3,000.00 (Single User License)

ID: GB19FFD0ED38EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030 Report Conclusions:

Number Of Gamma Delta T Cell Therapies In Trials: > 30 Therapies

US & China Dominating Clinical Trials Landscape: > 20 Therapies

Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase

Gamma Delta T Cell Therapy Future Market Opportunity By Different Cancers

Insight On Clinical Platforms for Evolving Gamma Delta T Cell Therapy: > 10 Platforms By Companies

Ongoing Clinical Research & Development Trends By Different Cancers

Insight On 12 Companies Developing Gamma Delta T Cell Therapies

After vicennium of futuristic T cells entrenched immunotherapy dominating the treatment landscape of cancer arena, there is a prerequisite to branch out cancer immunotherapy realm by developing other state-of-the-art therapies. But in spite of that, this led to discovery of other T cells receptors, such as gamma delta T cells, alpha-beta T cell and

others. Consecutively, finding of gamma delta T cells based immunotherapy (also recognized as $\gamma\delta$ T cells), it was further pragmatic that developing gamma delta T cells based immunotherapies will aid to offer a innovatory treatment for cancer along with other disorders, including viral infections, autoimmune and inflammation.

With respect to Kuick Research statistics, the global clinical conduit of gamma delta T cells based immunotherapy comprises of 30 drugs (as of June 2024), several of which are in preclinical stage as well as majority of research and development along with technological advancement in in this sector is ongoing in the US and China region. Albeit, no drug has penetrated into the commercial market to treat cancer or other ailments; however, as soon as one drug will get approved will aid to launch other gamma delta T cells based immunotherapy into market and clenches potential to become a multimillionaire market in imminent.

One of the strategic prime movers that bestow to bourgeon the growth of gamma delta T cells based immunotherapy market is the rise in preclinical and clinical studies. Over the preceding decennium, the sphere of global gamma delta T cells based immunotherapy market has witnessed the development of several novel, innovative as well as advanced competitors. For instance, a clinical-stage biotechnology company in US, Acepodia Biotech has developed 2 contenders, ACE1708 as well as ACE2016 to treat solid tumor expressing PD-L1 accompanied with EGFR expressing tumors.

Coupled with this, the presences of various stakeholders in conjugation with investors from giant pharma companies accompanied with biotech companies, such as Bristol Myers Squibb, TC Biopharm, PersonGen BioTherapeutics, In8bio, Kiromic BioPharma, Immatix, Legend Biotech, Innate Pharma, Ever Supreme Bio Technology, Editas Medicine, CytoMed Therapeutics, Acepodia Biotech and other have bestowed to transform the treatment paradigm by developing up-to-the-minute gamma delta T cells based immunotherapy worldwide. Amid all these companies, PersonGen BioTherapeutics is the frontrunner in this segment as the company is developing 5 allogeneic UCAR- $\gamma\delta$ T cell therapy for the treatment of autoimmune, T cell malignancies and other solid tumors. The presences of giant pharmaceuticals aid to conduct multitudinous clinical trials in gamma delta T cells based immunotherapy space.

Just as importantly, an inclining market trend towards developing avant-garde global gamma delta T cells based immunotherapy, such as developing gamma-delta gene editing based immunotherapy, is gaining spotlight amid healthcare professionals. For instance, a biotech company based in Germany, Immatix has collaborated with Bristol

Myers Squibb and Editas Medicine in order To syndicate gamma-delta T cell based adoptive cell therapies in addition to gene editing for the treatment of cancer.

Until now, no gamma delta T cells based immunotherapies has been approved in global market; nevertheless, it can be anticipated that a handful of gamma delta T cells therapies will be launched into the market in approaching 5 to 7 years due to the fact that many gamma delta T cells based immunotherapies have received FDA designations which aid to accelerate the approval process. For instance, ADI-001 has gained utmost breakthrough as it has received FDA fast track designation for the potential treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), in 2022, and relapsed/refractory class III or class IV lupus nephritis in June 2024. Overall, aforementioned illustrates clearly forecasts that the future of gamma delta T cells based immunotherapies will be propitious.

Contents

1. INTRODUCTION TO GAMMA DELTA T CELL THERAPY

- 1.1 Emerging Role of T Cell Based Immunotherapies
- 1.2 Overview of Gamma Delta T Cell Therapy
- 1.3 Gamma Delta T Cell Therapy v/s Conventional Therapies

2. ROLE OF GAMMA DELTA T CELLS IN CANCER

- 2.1 Gamma Delta T Cells in Cancer Progression
- 2.2 Anti Tumor Activity of Gamma Delta T Cells
- 2.3 Adopted Approaches for Gamma Delta T Cell Therapy

3. GLOBAL GAMMA DELTA T CELL THERAPY MARKET OVERVIEW

- 3.1 Current Market Scenario
- 3.2 Market Potential of Gamma Delta T Cell Therapy Market

4. GLOBAL GAMMA DELTA T CELL THERAPY CLINICAL TRIALS OVERVIEW

- 4.1 By Phase
- 4.2 By Country
- 4.3 By Company
- 4.4 By Indication
- 4.5 By Priority Status

5. GLOBAL GAMMA DELTA T CELL THERAPY CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE

- 5.1 Research
- 5.2 Preclinical
- 5.3 Phase I
- 5.4 Phase I/II
- 5.5 Phase II

6. GAMMA DELTA T CELL THERAPY IN LEUKEMIA

- 6.1 Ongoing Clinical Research & Development Trends

6.2 Future Market Opportunity of Gamma Delta T Cells in Leukemia

7. GAMMA DELTA T CELL THERAPY IN LUNG CANCER

7.1 Ongoing Clinical Research & Development Trends

7.2 Future Market Opportunity of Gamma Delta T Cell Therapy in Lung Cancer

8. GAMMA DELTA T CELLS IN BREAST CANCER

8.1 Ongoing Clinical Research & Development Trends

8.2 Future Market Opportunity of Gamma Delta T Cell Therapy in Breast Cancer

9. GAMMA DELTA T CELLS IN COLORECTAL CANCER

9.1 Ongoing Clinical Research & Development Trends

9.2 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer

10. GAMMA DELTA T CELLS IN PANCREATIC CANCER

10.1 Ongoing Clinical Research & Development Trends

10.2 Future Market Potential of Gamma Delta Therapy in Pancreatic Cancer

11. GAMMA DELTA T CELLS IN LYMPHOMA

11.1 Ongoing Clinical Research & Development Trends

11.2 Future Outlook in Lymphoma

12. GAMMA DELTA T CELL THERAPY IN BRAIN TUMORS

12.1 Research & Development in Brain Tumors

12.2 Future Outlook in Brain Tumors

13. GAMMA DELTA T CELL THERAPY IN HEAD & NECK CANCER

13.1 Research & Development in Head & Neck Cancer

13.2 Future Outlook in Head & Neck Cancer

14. GAMMA DELTA T CELL THERAPY IN AUTOIMMUNE, INFLAMMATORY & MICROBIAL AILMENTS

14.1 Research & Development in Autoimmune, Inflammatory & Microbial Ailments

15. COMBINATION METHODOLOGIES FOR GAMMA DELTA T CELL THERAPY

16. PLATFORMS FOR EVOLVING GAMMA DELTA T CELL THERAPY

17. GAMMA DELTA T CELL THERAPY MARKET DYNAMICS

17.1 Gamma Delta T Cell Therapy Market: Favorable Parameters

17.2 Gamma Delta T Cell Therapy Market: Challenges

18. COMPETITIVE LANDSCAPE

18.1 Acepodia

18.2 Adicet

18.3 Cytomed Therapeutics

18.4 Expression Therapeutics

18.5 Janssen Biotech

18.6 Gadeta

18.7 GammaDelta Therapeutics (Takeda)

18.8 IN8bio

18.9 Kiromic Biopharma

18.10 Lava Therapeutics

18.11 Regeneron Pharmaceuticals

18.12 TC Biopharm

I would like to order

Product name: Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030

Product link: <https://marketpublishers.com/r/GB19FFD0ED38EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB19FFD0ED38EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

